A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer

Paul A Foster; Simon P Newman; Mathew P Leese; Sonia Bernetiere; Christian Diolez; Jose Camara; Beatrice Hacher; Marie-Madeleine Baronnet; Tauhid Ali; Barry V L Potter; Michael J Reed; Atul Purohit

A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer

Paul A Foster, Simon P Newman, Mathew P Leese, Sonia Bernetiere, Christian Diolez, Jose Camara, Beatrice Hacher, Marie-Madeleine Baronnet, Tauhid Ali, Barry V L Potter, Michael J Reed, Atul Purohit

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

There is a continued need for orally bioavailable anticancer compounds that exhibit good efficacy against breast cancer. STX140, a derivative of 2-methoxyestradiol (2-MeOE2), has been shown to have excellent oral bioavailability and significantly reduces tumor growth. A new micronized formulation of STX140 has now been developed and its pharmacokinetics (PK) in rats and effect on MDA-MB-231 breast cancer growth in nude mice was investigated.

Original language	English
Pages (from-to)	577-81
Number of pages	5
Journal	Anticancer research
Volume	28
Issue number	2A
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{8a1742857af84159b4593403841410fc,

title = "A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer",

abstract = "There is a continued need for orally bioavailable anticancer compounds that exhibit good efficacy against breast cancer. STX140, a derivative of 2-methoxyestradiol (2-MeOE2), has been shown to have excellent oral bioavailability and significantly reduces tumor growth. A new micronized formulation of STX140 has now been developed and its pharmacokinetics (PK) in rats and effect on MDA-MB-231 breast cancer growth in nude mice was investigated.",

author = "Foster, \{Paul A\} and Newman, \{Simon P\} and Leese, \{Mathew P\} and Sonia Bernetiere and Christian Diolez and Jose Camara and Beatrice Hacher and Marie-Madeleine Baronnet and Tauhid Ali and Potter, \{Barry V L\} and Reed, \{Michael J\} and Atul Purohit",

year = "2008",

language = "English",

volume = "28",

pages = "577--81",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "2A",

}

TY - JOUR

T1 - A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer

AU - Foster, Paul A

AU - Newman, Simon P

AU - Leese, Mathew P

AU - Bernetiere, Sonia

AU - Diolez, Christian

AU - Camara, Jose

AU - Hacher, Beatrice

AU - Baronnet, Marie-Madeleine

AU - Ali, Tauhid

AU - Potter, Barry V L

AU - Reed, Michael J

AU - Purohit, Atul

PY - 2008

Y1 - 2008

N2 - There is a continued need for orally bioavailable anticancer compounds that exhibit good efficacy against breast cancer. STX140, a derivative of 2-methoxyestradiol (2-MeOE2), has been shown to have excellent oral bioavailability and significantly reduces tumor growth. A new micronized formulation of STX140 has now been developed and its pharmacokinetics (PK) in rats and effect on MDA-MB-231 breast cancer growth in nude mice was investigated.

AB - There is a continued need for orally bioavailable anticancer compounds that exhibit good efficacy against breast cancer. STX140, a derivative of 2-methoxyestradiol (2-MeOE2), has been shown to have excellent oral bioavailability and significantly reduces tumor growth. A new micronized formulation of STX140 has now been developed and its pharmacokinetics (PK) in rats and effect on MDA-MB-231 breast cancer growth in nude mice was investigated.

M3 - Article

C2 - 18506995

SN - 0250-7005

VL - 28

SP - 577

EP - 581

JO - Anticancer research

JF - Anticancer research

IS - 2A

ER -

A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer

Abstract

UN SDGs

Fingerprint

Cite this